The House’s Cut is Going Up
Motley Fool Money
00:00
Eli Lilly's Manjaro: A Game-Changer in Weight Loss Pharmaceuticals
This chapter explores the competitive dynamics between Nova Nordisk and Eli Lilly, particularly focusing on Eli Lilly's weight-loss drug, Manjaro. It delves into the drug's innovative mechanisms, pricing strategies, and sales projections while also lightening the mood with insights into the naming process of pharmaceutical products.
Play episode from 17:37
Transcript
